A Phase 1, Open-Label, Crossover Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects.

Trial Profile

A Phase 1, Open-Label, Crossover Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2013

At a glance

  • Drugs Cabotegravir (Primary) ; Dolutegravir (Primary) ; Rilpivirine (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 26 Aug 2013 Results published in the Antimicrobial Agents and Chemotherapy.
    • 01 Jun 2012 Actual number of patients changed from 44 to 56, as reported by ClinicalTrials.gov.
    • 22 Mar 2012 Actual patient number (44) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top